GLP-1 Drugs Explained: What Ozempic and Wegovy Actually Do to Your Body

GLP-1 receptor agonists — commonly known by brand names like Ozempic, Wegovy, and Mounjaro — have become the most talked-about medications of the decade. Originally developed to treat type 2 diabetes, these drugs are now being studied and prescribed for a surprising range of conditions.

What Is a GLP-1 Drug?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after you eat. It signals your pancreas to produce insulin, tells your liver to stop releasing sugar, and — crucially — tells your brain that you're full.

GLP-1 drugs mimic this hormone, but in a far more powerful and sustained way than your body naturally produces it. The result? Lower blood sugar, slower digestion, and significantly reduced appetite.

Why Is Everyone Talking About Ozempic?

Ozempic (semaglutide) was approved by the FDA in 2017 for type 2 diabetes management. But something unexpected happened in clinical trials: patients were losing substantial amounts of weight — 10 to 15% of their body weight in some cases.

This led to the development of Wegovy, a higher-dose version of semaglutide specifically approved for chronic weight management in 2021. Clinical trials showed participants lost an average of 15% of their body weight over 68 weeks — far more than any previous weight-loss drug.

What Conditions Can GLP-1 Drugs Treat?

Research has expanded well beyond diabetes and obesity. Here's what the evidence currently supports:

Obesity and weight management — The most well-established use outside of diabetes. Wegovy and similar drugs produce meaningful, sustained weight loss when combined with lifestyle changes.

Cardiovascular disease — A landmark 2023 trial (SELECT) showed semaglutide reduced the risk of major cardiovascular events (heart attack, stroke) by 20% in people with obesity but without diabetes. This was a major turning point.

Kidney disease — Trials show GLP-1 drugs slow the progression of chronic kidney disease, likely by reducing inflammation and improving blood sugar control.

Fatty liver disease — Early data suggests significant improvements in non-alcoholic fatty liver disease (NAFLD), with some patients seeing near-complete reversal.

Sleep apnea — A 2024 trial found semaglutide reduced sleep apnea severity by over 50% in obese patients.

Addiction — Researchers are exploring whether GLP-1 drugs reduce cravings for alcohol, nicotine, and other substances. Early results are intriguing.

How Do You Take GLP-1 Drugs?

Most are administered as a weekly subcutaneous injection — a small needle injected under the skin, usually in the abdomen, thigh, or upper arm. Oral versions (like Rybelsus) also exist for some patients.

Doses are typically started low and gradually increased over several months to minimize side effects.

What Are the Side Effects?

The most common side effects are gastrointestinal:

Nausea (very common, especially early on)
Vomiting
Diarrhea or constipation
Stomach discomfort

These usually improve as your body adjusts. More serious but rare risks include pancreatitis and, in animal studies (not confirmed in humans), thyroid tumors — which is why they're not recommended for people with a personal or family history of certain thyroid cancers.

Who Should Not Take GLP-1 Drugs?

GLP-1 drugs are not appropriate for everyone. They are typically not prescribed to:

Pregnant or breastfeeding women
People with a personal or family history of medullary thyroid carcinoma
Those with a history of pancreatitis
People with type 1 diabetes (in most cases)

Always discuss with your doctor whether these medications are right for you.

Are They a Cure or a Lifelong Commitment?

This is the critical question. Studies show that most people regain a significant portion of lost weight within a year of stopping the medication. This suggests GLP-1 drugs treat the condition of obesity rather than cure it — similar to how blood pressure medication works. Many patients may need to take them indefinitely.

The Cost Problem

The biggest barrier for most people is cost. Wegovy can cost over $1,300 per month in the US without insurance. Coverage varies widely, and many insurers still classify these drugs as "lifestyle medications" rather than medical necessities.

Generic versions are expected to become available later this decade, which could dramatically change access.

The Bottom Line

GLP-1 drugs represent a genuine breakthrough in medicine. For the right patient, they offer benefits that go far beyond the scale — protecting the heart, kidneys, and liver in ways no previous weight-loss drug could. But they are not magic pills. They work best alongside dietary changes, exercise, and ongoing medical supervision.

If you're curious whether a GLP-1 medication might be right for you, talk to your doctor. The conversation is worth having.